⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Manina Medtech and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Manina Medtech
↗Barcelona, Spain
Manina Medtech is a Barcelona-based medical technology startup and spin-off from the Vall d'Hebron Research Institute. The company focuses on improving In Vitro Fertilization (IVF) outcomes by addressing the unmet need for objective, real-time assessment of uterine receptivity during embryo transfer.
Their flagship technology, Seedchrony, is a non-invasive medical device that combines hardware, software, and AI to evaluate the endometrial environment without the need for traditional biopsies. By providing clinicians with immediate data, the system aims to optimize the timing of embryo transfers and increase pregnancy success rates.
CLASSIFICATION
Company Type:MedTech
Therapeutic Areas:-
Industry:Medical Devices
Sub-Industry:Digital Health / Reproductive Health
SIZE & FINANCIALS
Employees:1-50
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Seed
PIPELINE
Stage:Clinical
Lead Drug Stage:Clinical Trial (Seedchrony)
Modalities:Medical Device, AI/ML Software
Active Trials:1
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Vall d'Hebron Research Institute (Spin-off origin), CRA Barcelona (Clinical collaboration)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Mónica Rodríguez de la Vega - CEO / Co-Founder
Luis Artiles - COO / CTO / Co-Founder
Anna Puigdollers - CFO
Scientific Founders:Mónica Rodríguez de la Vega, Luis Artiles
LINKS
Website:maninamedtech.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Manina Medtech. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.